Details of the Drug Reposition

General Information of This Drug (ID: DMEB837)

Drug Name
Cefotaxime   DMEB837
Synonyms
Cefotaxima; Cefotaxima [INN-Spanish]; Cefotaxime [INN:BAN]; Cefotaxime acid; Cefotaximum; Cefotaximum [INN-Latin]; Cephotaxime; E-cefotaxime; Omnatax; RU 24662; RU 24756; cefotaxime; 5-Thia-1-azabicyclo(4.2.0)oct-2-ene-2-carboxylic acid, 3-((acetyloxy)methyl)-7-(((2Z)-(2-amino-4-thiazolyl)(methoxyimino)acetyl)amino)-8-oxo-, (6R,7R)-; 60846-21-1; 63527-52-6; C16H17N5O7S2; CHEBI:204928; EINECS 264-299-1; HR 756; N2GI8B1GK7; Taxim; UNII-N2GI8B1GK7
Structure
3D MOL 2D MOL

Information on Drug Reposition of This Drug

Molecular Interaction Atlas (MIA)
8 Approved Indication(s)
Indication Name Indication ID ICD-11 Status REF
Staphylococcal pneumonia DIS28ZSZ N.A. Approved [1]
Peritonitis DISMCMLQ N.A. Approved [1]
Neonatal sepsis DIS8Q3VE N.A. Approved [1]
Meningococcal meningitis DISCKTAT N.A. Approved [1]
Escherichia coli meningitis DISN1LGK N.A. Approved [1]
Bacterial arthritis DIS8R241 N.A. Approved [1]
Bacterial infection DIS5QJ9S 1A00-1C4Z Approved [2]
Bacteremia DIS6N9RZ 1A73 Approved [1]
------------------------------------------------------------------------------------
⏷ Show the Full List of 8 Indications(s)
1 Discontinued in Phase 3 Indication(s)
Indication Name Indication ID ICD-11 Status REF
Bacterial pneumonia DISPW7PH CA40.0 Discontinued in Phase 3 [3]
------------------------------------------------------------------------------------
2 Discontinued in Phase 2 Indication(s)
Indication Name Indication ID ICD-11 Status REF
Bacterial urinary tract infection DISNNJTF N.A. Discontinued in Phase 2 [4]
Bacterial meningitis DISRP9SL N.A. Discontinued in Phase 2 [5]
------------------------------------------------------------------------------------
2 Discontinued in Phase 1 Indication(s)
Indication Name Indication ID ICD-11 Status REF
Ophthalmia neonatorum DISR74MC N.A. Discontinued in Phase 1 [6]
Streptococcal meningitis DISQ65JM N.A. Discontinued in Phase 1 [7]
------------------------------------------------------------------------------------

References

1 Cefotaxime FDA Label
2 FDA Approved Drug Products from FDA Official Website. 2009. Application Number: (ANDA) 064200.
3 One-Year Trial of Oral Ziprasidone in Bipolar Patients With Metabolic Syndrome
4 Modafinil for Methamphetamine Dependence
5 Efficacy Study of SIMVASTATIN to Treat Chronic Rhinosinusitis After Failure of Optimal Treatment
6 Reduced Intensity Transplant in Medically Refractory Systemic Lupus Erythematosus (SLE) and Systemic Sclerosis (SSc)
7 Treated Blood Cells, Cyclophosphamide, Fludarabine Phosphate, and Aldesleukin in Treating Patients With Cancer